Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Dicerna nets $108mm via FOPO

Executive Summary

Dicerna Pharmaceuticals Inc. (develops RNAi therapeutics) netted $108mm through a follow-on public offering of 8.83mm common shares (including full exercise of the overallotment) at $13.02. The company plans to use some of the funds for preclinical and clinical studies and ongoing development of its technology platform.
Deal Industry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
    • Nanotechnology, Chips, etc.
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
      • Site Specific
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies